Amid a blitz of advertising, patients and their physicians are left to weigh the pros and the cons of the blood thinners currently on the market, taking into consideration cost, convenience, and safety. Xarelto lawsuits continue to mount leading patients to consider how safe this new generation anticoagulant is.
The FDA approved the use of testosterone replacement products only for men who don’t produce enough testosterone because of a medical condition called hypogonadism. According to testosterone treatment lawyers, the lawsuits allege that the drug companies took their marketing way beyond that.
AstraZeneca Plc’s diabetes drug Onglyza has a broadly acceptable cardiovascular safety profile but its label should include new information about the risk of heart failure, a U.S. Food and Drug Administration advisory panel concluded on Tuesday.